

Health And Trade - Investigating The 2014 Ebola Outbreak

Marius Gruenewald

marius_gruenewald@web.de

01.05.2019

Department of Economics, UW - Madison


Abstract

Over the last years, research on the impact of globalization on health has sky-rocketed. Despite, there has been, to the best of my knowledge, no research that investigates the reverse causality. This gap gives the main motivation for my research design. I offer a first step for a theoretical consideration of health determined trade. Later, the suggested identification strategy for empirical estimation is a natural experiment. I argue that the 2014 Ebola outbreak in western Africa can be treated as such by providing mostly anecdotal evidence. Lastly, a discussion of data will be provided.

1 Motivation

Over the course of the last years there has been a surge of scholastic studies dealing with the consequences of globalization on health outcomes (the Lancet series on trade and health). This is not surprising given the interesting data connection we observe when comparing the time trends as shown in figure 1.

Figure 1: Exports and Health



There is an obvious correlation in the data. Correlations usually leave us with the question of whether a causal mechanism is in play, and if, in which direction, or it follows a third common factor.

A brief literature review lays out an expansive body of literature investigating the effect of trade on health. Most notably, a Lancet series including contributions by Stiglitz (2009) and Smith et al. (2009) and outside the series Lopez et al. (2017). Yet, valuable insight can be gained by considering the literature investigating the relationship of health on growth, since approaches and methods are closely aligned. Weil (2014) offers an excellent literature review of the related topic. More recently, Bloom et al. (2018) discuss the topic with respect to empirical difficulties and contextual issues.

2 Literature Review

2.1 Trade and Health

2.2 History of Ebola

3 Theoretical Part

3.1 A baseline international real business cycle model

3.1.1 The Environment

Broadly speaking, I follow the environment drawn by Backus et al. (1992) or Kim and Kim (2003). In this environment, there are two symmetric countries, 1 and 2, with complete markets and production where labour is endogenized with respect to health but not included in the utility function. The households exhibit the utility function

$$\mathbf{E}_0 \sum_{t=0}^{\infty} \beta^t U(C_{1,t}) \quad (1)$$

$$\mathbf{E}_0 \sum_{t=0}^{\infty} \beta^t U(C_{2,t}) \quad (2)$$

where the foreign country has the subscript 2. Production occurs in the usual Cobb-Douglas fashion.

$$Y_{1,t} = A_{1,t} N_{1,t}^{1-\alpha} K_{1,t}^{\alpha} \quad (3)$$

$$Y_{2,t} = A_{2,t} N_{2,t}^{1-\alpha} K_{2,t}^{\alpha} \quad (4)$$

where

$$\ln A_{1,t} = \rho^A \ln A_{1,t-1} + H_{1,t} \quad (5)$$

$$\ln A_{2,t} = \rho^A \ln A_{2,t-1} + H_{2,t} \quad (6)$$

$$\ln N_{1,t} = \rho^N \ln N_{1,t-1} + H_{1,t} \quad (7)$$

$$\ln N_{2,t} = \rho^N \ln N_{2,t-1} + H_{2,t} \quad (8)$$

Productivity and labour supply follow a stochastic process with additional dependence on health, with this health measure $H_{i,t}$ for $i = 1, 2$ following

$$H_t = \rho^H H_{t-1} + \epsilon \quad (9)$$

Both countries face a budget constraint such that

$$Y_{1,t} + D_{1,t+1} = C_{1,t} + I_{1,t} + (1+r)D_{1,t} \quad (10)$$

or

$$Y_{2,t} + D_{2,t+1} = C_{2,t} + I_{2,t} + (1+r)D_{2,t} \quad (11)$$

where D denotes debt and I investment in capital as $I_{1,t} = K_{1,t+1} - (1 - \delta)K_{1,t}$ or $I_{2,t} = K_{2,t+1} - (1 - \delta)K_{2,t}$ respectively. The world interest rate r is assumed to be exogenously given as is the depreciation rate δ . To ensure non-explosive results, the no-Ponzi-scheme condition has to hold.

$$\lim_{t \rightarrow \infty} \mathbf{E}_t \frac{D_{t+1}}{(1+r)^t} \leq 0 \quad (12)$$

It states that the household has to pay back accumulated debt eventually. Any shock to health follows

$$\epsilon \sim \mathcal{N}(0, \sigma^2) \quad (13)$$

with no spillovers and no correlation to shocks in the other country.

3.1.2 Decentralized solution

To obtain analytical results, let the utility function of households for both countries be characterized by the isoelastic form of

$$U(C_t) = \frac{C_t^{1-\gamma}}{1-\gamma} \quad (14)$$

With this information, we can set up the Langrangian and maximize for C_t , K_{t+1} and D_{t+1} for each country separately such that conditions (3) - (10) hold. To ease the mathematical proceeding, I substitute expressions for I_t and Y_t . In mathematical terms this can be expressed as

$$\begin{aligned} \mathcal{L} = \mathbf{E}_0 \sum_{t=0}^{\infty} \beta^t & \left[U(C_{i,t}) \right. \\ & \left. - \lambda_t^1 \left(C_{i,t} + K_{i,t+1} - (1 - \delta)K_{i,t} + (1 + r)D_{i,t} - A_{i,t}N_{i,t}^{1-\alpha}K_{i,t}^{\alpha} + D_{i,t+1} \right) \right] \end{aligned}$$

for $i = 1, 2$. When combining the first-order conditions we obtain the consumption Euler as

$$C_{1,t}^{-\gamma} = \beta C_{1,t+1}^{-\gamma} (1 - \delta + \alpha A_{1,t+1} N_{1,t+1}^{1-\alpha} K_{1,t+1}^{\alpha-1}) \quad (15)$$

Due to symmetry, country 2 shows the same optimization process and the Euler equation is

$$C_{2,t}^{-\gamma} = \beta C_{2,t+1}^{-\gamma} (1 - \delta + \alpha A_{2,t+1} N_{2,t+1}^{1-\alpha} K_{2,t+1}^{\alpha-1}) \quad (16)$$

Additionally, the involvement of $D_{i,t}$ requires that

$$C_{1,t}^{-\gamma} = \beta(1+r)C_{1,t+1} \quad (17)$$

$$\text{and} \quad (18)$$

$$C_{2,t}^{-\gamma} = \beta(1+r)C_{2,t+1} \quad (19)$$

Subsequently, we can characterize the equilibrium for country 1 with equations (3), (5), (7), (10), (15) and (17). Country two needs (4), (6), (8), (11), (16) and (18) to find a steady-state solution.

The last step is to calculate exports, imports and the trade balance. Since the simple model has only one good, the amount exported equals the total production of the economy. As a result, the imports have to equal the amount of consumption plus any investment made. Lastly, the trade balance is defined as the difference between exports and imports.

3.2 Simulation of the baseline model

To see the implication of health to trade outcomes, I simulate a health shock following (9) and (12). Assumingly, the economy starts in the steady-state when the shock occurs. To ensure comparability to the empirical part of this study, I simulate a shock only to country 1 and consider a model in years. All simulation are done with dynare (Adjemian et al. (2011)).

Since the model contains several exogenous parameters, a discussion of these is obligatory. Values for γ , α , ρ^A , r and δ are from Schmitt-Grohé and Uribe (2003). ρ^N is the persistence of shocks to labour. Smets and Wouters (2007) provide the value. ρ^H measures the persistence of health shocks. Naturally, the persistence of health shocks varies widely depending on the disease. For Ebola, Fisman et al. (2014) state an overall infection period of 15 days. Therefore, I set ρ^H to 0.041 for an annual analysis.

σ^2 is the variance in the persistence of Ebola cases. Following the data provided by Fisman et al. (2014) this equals to approximately 9 days or a parameter value of 0.024.

Table 1: Calibration

| Parameter | Description | Value |
|-----------|------------------------------------|-------|
| γ | Utility parameter | 2 |
| α | Capital share of output | 0.34 |
| ρ^A | Persistence of productivity shocks | 0.42 |
| r | World interest rate | 0.04 |
| δ | Depreciation rate | 0.1 |
| ρ^N | Depreciation rate | 0.5 |
| ρ^H | Persistence of health shocks | 0.04 |
| σ | Std. dev. of health shock | 0.05 |

With these parameters, we can simulate the shock to an economy. Log-linearization is performed by Dynare. Further, I apply an Hodrick-Prescott filter with a lambda value of 6.25 as suggested by Ravn and Uhlig (2002). The Taylor approximation is set to be first order only. In table 2, I report the estimated second order coefficient for exports, imports and net exports as estimated by the simple model. To see how well these coefficients compare to the real data, I report the standard deviation of differenced data for the treated countries once

the shock happened.

Table 2: Estimated Second Order Moments

| Variable | Estimated Variance | Variance in Data |
|------------------------|--------------------|------------------|
| Exports | 0.04 | 2.05 |
| Imports | 0.001 | 1.9 |
| Net Exports (% of GDP) | 0.04 | 0.000 |


Clearly, these moments are not well matched. However, this should not be a surprise. Not only, is the model missing many potential channels of but, more importantly, the horizon is quite different. The real data lasts exactly three years, while the simulated data lasts 80. Since the shock demonstrates the greatest steady-state distortion on impact, we would expect a higher variance for data that only captures these first periods. Interestingly, the variance for the trade balance relative to GDP is smaller in the real data than in the simulation. This indicates, that the simulated impact on net exports might be overstating the real world impact. A priori to the empirical analysis, we expect the simple model to perform poorly when predicting trade balances response, while we cannot rule out an unrealistic performance of response in exports and imports. Albeit the limited use of comparing second order moments, simulated impulse response function can be a valuable addition. With them, we are able to compare the direct impact estimated in the model with the direct impact in the real data as done in the following section. Any further-going simulations can be interpreted as a prediction of future development.

Figure 2 shows the impulse response functions of the health shock to exports, imports and net exports as a share of GDP. We see a strong drop in exports on impact. This is unsurprising since any negative change in health reduces productivity and labour supply directly. Both factors are direct components of the nation's output which equals exports as outlined earlier. In the second period after the shock, exports start to converge towards its steady-state level based on the diminishing effects of the shock slowly increasing output. The model suggests the convergence to last up to 60 years.

The effect on imports is different. On impact, imports decrease but by a smaller margin than the exports. That is because consumers want to smooth consumption which can on impact be achieved by increasing debt. That means imports drop less. Immediately after, imports increase and even surpass the steady-state level. Since labour supply and productivity start to converge back to steady-state level, the gains of that are being distributed between pay back debt, higher consumption and more investment. Higher consumption and investment mean increased imports.

The trade balance is by definition the difference between exports and imports. It therefore follows the export's behaviour simply because the direct impact on exports is significantly stronger than the indirect impact on imports but on a

Figure 2: Baseline Simulation



wider amplitude incorporating the increased imports from period two onwards. The behaviour of other model variables of the home and foreign country is portrayed in table 14 and 15 in the appendix.

If we were to believe this model as the true model, we would expect the empirical estimation to yield on impact negative coefficient of health for every dependent variable of interest exposed above. Empirical impulse response function should show statistical insignificance of health regressed on exports in the following two to three years and then significantly positive results. After the contemporaneous effect, the estimated coefficient for health should turn positive. All with a smaller coefficient, however. The coefficient of a health measure on trade balance is expected to behave as the estimated coefficient for health on exports.

3.3 Expanded model

4 Empirics

4.1 Regression design

In order to find out where to start when doing the empirical analysis, we can turn to the simple benchmark model again. We saw there that the primary

influence of health shocks are via the production function

$$Y_{i,t} = A_{i,t} N_{i,t}^{1-\alpha} K_{i,t}^{\alpha}$$

Afterwards, we take the logarithm to receive

$$\ln Y_{i,t} = \ln A_{i,t} + (1 - \alpha) \ln N_{i,t} + \alpha \ln K_{i,t}$$

Finally, we substitute a generalized version of (5)-(6) as well as (7)-(8) and collect terms.

$$\ln Y_{i,t} = (2 - \alpha) H_{i,t} + \rho^A \ln A_{i,t-1} + (1 - \alpha) \rho^N \ln N_{i,t-1} + \alpha \ln K_{i,t} \quad (20)$$

Since production in the simple model equals exports, we can see (20) as the benchmark regression to determine the impact of health shocks on exports. Since $H_{i,t}$ follows a stochastic process in the model, an instrumental variable approach seems natural. If we are able to identify a shock to health, we can use the shock to predict a health measure and subsequently test for the impact on exports, imports and trade balance.

4.2 The ideal experiment

In an ideal setting, one would like to have a comprehensive administrative dataset at the individual level. This should at least state whether a person had Ebola and demographic statistics such as age. Additionally we would need firm data on exports and imports or, in case of self-employment the individual's trading data. Lastly, we would have to link each person not self-employed to its employer. With all this information we are able to construct a micro-level analysis. That is advantageous because Ebola itself, like a health issue, is a problem that occurs on an individual level. We would be able to track the consequences perfectly.

Unsurprisingly, there is a lack of data. The most glaring lack is demographic data. The latest county population data in Guinea, for instance, are from 2011 which makes them better suited for other research. Surveys, unfortunately, are not conducted in sufficiently small time intervals. Moreover, firm-level data is missing, too.

Luckily, country-level data are complete and available. Therefore, we have to trade the heterogeneity occurring on more filigree levels with having data at all. This is far from perfect but allows to continue investigating.

4.3 Measuring Health


4.3.1 Standard Inflammatory Response Model

The Standard Inflammatory Response (SIR) model has been used in epidemiology since its discovery by Kermack and McKendrick (1927). Nowadays, it is

a standard model in describing the transmission dynamics of epidemic diseases. It is not only used in epidemiology, as in Shulgin et al. (1998) but also in mathematics (McCluskey (2010)) and ecology (Bjørnstad et al. (2002)). In economics, the model is employed in Hansen et al. (2017).

Generally, the model separates individuals into either *Susceptible*, *Infected* or *Recovered*. A certain number of individuals has a chance to remain in the same category or change to a different category at the beginning of each new period. Death can potentially occur at any group however with different probabilities. Additionally, there is a certain amount of new people born every period entering as *Susceptibles*. Figure 3 puts the mechanics in a space graph following the representation of Bhattacharya et al. (2013).

Figure 3: Schematic SIR



$b_t S_t$ equals the number of all births in t , with b_t being the birth rate and S_t the number of non-infected individuals, the *Susceptibles* that are not immune. $\lambda_t^{DS} S_t$ represents the amount of non-immune people dying of other causes than the disease of interest. All immune people, the *Recovered*, dying in t are captured by $\lambda_t^{DR} R_t$. This group consists of all people being vaccinated $\nu_t S_t$ and those having recovered from the disease $\lambda_t^{RI} I_t$ with the recovery rate λ_t^R . The total number of new infection is given by $\lambda_t^{SI} S_t$. The death toll of the disease is stated with $\lambda_t^{DI} I_t$.

To model the Ebola epidemic, the standard model needs some minor adjustments. Hereby, I follow Hansen et al. (2017) in modelling the SIR model and discretizing the model to ease the transition to the empirical estimation.

Firstly, I consider the *Susceptibles*. This pool of non-infected, non-immunized person develops according to

$$S_{t+1} = S_t + b(S_t + R_t) - \lambda_t^{SI} S_t - \lambda_t^{DS} S_t$$

where b is a exogenously given birth rate. New-borns are automatically entering as susceptibles. This is a simplifying assumption since Dörnemann et al. (2017) give proof of babies born to Ebola-virus positive women inheriting the virus. However, it does not alter the results justifying this simplification. Further, I assume that infected women are not able to give birth. This, as well, is not true but due to limited cases not changing the findings (Baggi et al. (2014)). λ_t^{SI} is the infection rate of Ebola and λ_t^{DS} represents the exogenous death rate due to other causes than Ebola.

$$R_{t+1} = R_t + \lambda_t^R I_t - \lambda_t^{DR} R_t$$

explains the motion of recovered agents with λ_t^R being the recovery rate. λ_t^{DR} describes the death rate of people having recovered from Ebola. This is exogenously given and may or may not differ from λ_t^{DS} . $\nu_t R_t \equiv 0$, since there is no vaccine for Ebola at the time being, although progress towards it has been made (Ledgerwood et al. (2017)).

The remaining group of the population is the infected. In essence, the infected follow

$$I_{t+1} = I_t + \lambda_t^{SI} S_t - \lambda_t^{Eb} I_t - \lambda_t^I R_t$$

the infection rate λ_t^{SI} is exogenously given, as is λ_t^{Eb} , the Ebola death rate among infected. Unsurprisingly, the rate of recovery for Ebola λ_t^I is exogenous, too.

With this in mind we can formulate a Ebola-related case prevalence rate.

$$CP_t^{Eb} = \frac{I_t}{P_t} = \frac{I_t}{S_t + R_t + I_t}$$

There are several reasons for doing so. Firstly, effects such as changes in consumer behaviour do not have to be associated to deaths but could be as well associated to the infection whether deadly or not. Secondly, the number of workers is defined as the uninfected portion of the population. So capturing the mortality rate would ignore the number of infected unable to work. Lastly, as

long as recovery rate and death rate of the disease are constant the case prevalence and mortality rate will be highly correlated. And indeed, the correlation coefficient is approximately 0.7.

REPHRASE FROM HERE ON.
COMBINE VIA ARGUING FOR CASE PREVALENCE

When it comes to measuring health, there are two obvious choices occurring widely in the literature, mortality rate and life expectancy. They are closely related since life expectancy is defined as

$$LE(n, x) = 1 - e^{n * m(n, x)} \quad (21)$$

where $m(n, x)$ is the age-specific mortality rate starting at age x to age $n + x$. Therefore, a considerable change occurs mostly at interpretation of any results. Generally, the literature has been looking at life expectancy at birth as a measure for health, for instance consider Bloom et al. (2018), Acemoglu and Johnson (2007) or Bloom et al. (2014). This seems to be a sensitive measure for long term if the overall objective is to collect all possible effects happening during a lifetime. For instance, it captures reduced child mortality as well as better medication for HIV which can prolong live at an adult stage as well. However, trends across countries and age group can differ substantially as highlighted by McMichael et al. (2004). Given this heterogeneity in trends, only looking at life expectancy at birth might be misleading, especially since section II outlines that many effects, such as productivity decline or available workers which does not apply to infants. Therefore, I will use adult mortality rate as a baseline result, since it excludes changes in mortality due to improvements in survival rate during life childbirth.

Yet, in a more dynamic perspective it might be that less stress of the mother while bearing the child could potentially increase productivity and education, as the fetal origin hypothesis suggests¹. In addition, Norman et al. (2012) point out the severe consequences of a diverse range of mental and physical abuses can have on a person's live. These include a higher suicide rate, drug use and mental disorder.

Lastly, I consider infant mortality rate, too. By doing so, we can do an valuable robustness check to see whether there is heterogeneity across age groups and whether we should subsequently interpret the estimated results for regular adult mortality as an upper or lower bound. Table3 summarizes these measures.

Life expectancy and mortality data are taken from the World Health Organization (2018) and their Global Health Workforce Statistics. One might notice the high number of observations. This originates in the structure of the trade data, which are measured in country pairs. A more careful explanation of the

¹Almond and Currie (2011) give a more detailed introduction to this theory and further provide a cohesive literature review.

Table 3: Main Health Measures

| Variable | Mean | Std. Dev. | Min. | Max. | N |
|-----------------------|--------|-----------|------|------|-----|
| Adult mortality rate | 339.46 | 97.36 | 185 | 637 | 680 |
| Life expectancy | 56.20 | 5.52 | 39.8 | 68.7 | 680 |
| Infant mortality rate | 69.065 | 22.247 | 26.1 | 142 | 680 |

reasons to measure trade with country-pairs will be provided later. Further measures could be Anemia, neonatal mortality rate or birth weight (Weil (2014)) or even include crude data such as death rate. These additional measures for health are displayed in table 15 in the appendix. These additional data are taken from The World Bank (2017).

4.3.2 Ebola

Contrary to health, Ebola measures are less discussed in the literature but abundantly available. Data on Ebola cases and deaths are from the situation report by the World Health Organisation (2016) and occur in a high frequency which has been exploited by studies such as Gonzalez-Torres and Esposito (2017) or Althaus (2014). The lack of high-frequency data in the areas of population and trade however, force me to aggregate to a yearly level losing heterogeneity across time. While Ebola cases and deaths are not only the most intuitive measure but also of reliable quality, it might make sense to expand the set of measurements.


Big data has helped epidemic research substantially in predicting outbreaks of different diseases, consider Ginsberg et al. (2009) as an example, as well as their surveilling (e.g. Chan et al. (2011)). I consider the number of New York Times Articles about Ebola in a given country in a given year as an additional measurement. Even though it can't be literally defined as big data it shows remarkable similarities as shown in figure 4, where both number are scaled to be between 100 and 0 with 100 being the month with the most queries/articles.

The rationale is to include a "foreign perspective" so that it might capture effects better if the unaffected country's parameters, for instance ω_t^* or Ω_t^* , are the true driving forces behind the change of behaviour. Naturally, we expect a high, statistical significant correlation with the number of Ebola cases and yet a respectable distance to a perfect correlation represented by 1. The sample correlation with 0.633 seems to confirm the intuition.

On the other hand, there are disadvantages when using this measure. Firstly, we assume that the NYT has no inherent bias towards certain countries in the study. This is part of the reason for choosing the NYT since countries with a colonial link might show higher temptation to report on the former colony. The United States do not have a past a colonizer but regardless might exhibit a bias towards the English-speaking countries in the sample, in particular Sierra-Leone and Liberia.

Secondly, we might overestimate the effect of ω_t^* and Ω_t^* if the interest of the

Figure 4: NYT and Google



NYT in Ebola is higher than of the representative consumer. Similarly, we underestimate if the interest of the newspaper abates while the household is still concerned about Ebola. An example could be that a major event in a different foreign country takes up the space of limited lines in the newspaper. Lastly, we arguably worry about an US newspaper representing the entirety of global demand we is likely to be very heterogeneous and only coincidentally on average similar if we're refusing to assume a preference shaping role of the US. Table 4 shows a summary of the discussed measures.

Table 4: Ebola Measures

| Variable | Mean | Std. Dev. | Min. | Max. | N |
|----------------|--------|-----------|------|-------|-----|
| Ebola cases | 84.091 | 815.583 | 0 | 14122 | 680 |
| Ebola deaths | 12.238 | 163.731 | 0 | 2536 | 680 |
| Ebola articles | 2.568 | 29.123 | 0 | 527 | 680 |

Since this study focuses on the 2014 Ebola outbreak only, outbreaks in different countries at previous or following years are being ignored. Prime example is the 2000-2001 outbreak in Uganda. This is potentially problematic as it can violate the assumption of common Pre-Trends. Further, countries with limited or local cases in 2014 such as Senegal or Nigeria are equally ignored. If these limited outbreaks do indeed have an impact on the mortality rate, it causes the results to be biased. The country-pair structure of the data allows us to exclude relevant observations and effectively correct for any potential bias.

4.3.3 Trade Measures

The previous sections have already hinted that I will be using country-pair trade data. The chapters also provided some reasons for doing so. We can exclude direct neighbours to Ebola affected countries and therefore control for spillover effects, we can omit countries having had limited outbreak and subsequently

exclude them to see for any biased estimates and we can omit countries with periods of any sort of epidemic, Ebola or other, potentially violating the common trends assumption.

Table 5: Trade Measures

| Trade Data | | | | | |
|--------------------------|--------|-----------|-------|--------|-------|
| Variable | Mean | Std. Dev. | Min. | Max. | N |
| Imports (% of GDP) | 0.014 | 0.173 | 0 | 14.825 | 63537 |
| Exports (% of GDP) | 0.006 | 0.07 | 0 | 3.669 | 57261 |
| Trade Balance (% of GDP) | -0.004 | 0.087 | -5.22 | 2.597 | 83428 |

Naturally, the gravity approach increases the amount of observations drastically. In order to normalize the the crude export and import values, I divided each by the country's corresponding GDP value so that terms relative to GDP are obtained. The directions of trade dataset by the International Monetary Fund (2017) provides the bilateral trade data.

4.4 First Stage

Empirical estimation is difficult. This is mainly because causal relationships can not only work from health to trade, as I try to investigate, but obviously in the reverse order as well, as emphasized in section I. Additionally, one has to worry about a third, omitted variable that drives both trends simultaneously. Economic growth could be such a driver. Therefore, I suggest to employ a natural experiment to solve the issue of identification. The 2014 Ebola outbreak in Westafrica, in particular in Guinea, Liberia and Sierra-Leone, is such which allows me to employ a difference-in-differences (DiD) approach. The baseline estimation regression is

$$H_{it} = \beta Z_{it} + Q'_{it}\gamma + \pi_{it} + \alpha_i + \gamma_t + \epsilon_{it} \quad (22)$$


where i indexes the country-pairs and t time. Y_{it} captures the outcome variable measuring health, age-adjusted adult mortality rate, while Z_{it} is our variable of interest - Ebola - with β the corresponding coefficient. Both are scalars at time t for unit i . The vector Q_{it} is of rank $K \times 1$ with K being the number of controls for each unit at each time added to the regression. In the baseline estimation, the control vector will remain a scalar containing only a linear time-trend for each country. An extended model includes up to α_i and γ_t scalars for country- and time-fixed effects, respectively. γ_t controls for differences across years common to all states and α_i for differences across countries occurring to all states. π_{it} is a country-pair specific, linear trend over time. The idiosyncratic error term is represented by ϵ_{it} .

However, reasoning is mandatory since a natural experiment in the sense of a DID requires common trends between treatment and control group before the treatment. Hereby arises a first question of how to select a control group. This is not a trivial task since simply taking all other countries as control group certainly forces the common trends to fail. To begin with, we need to ensure that the disease environment is approximately equal across sample countries. If there was a significant difference in the probability of an epidemic due to environmental circumstances as temperature, we would not have a random assignment of the treatment making use of policy evaluation unsuitable.

Secondly, a functioning health infrastructure can significantly limit the likelihood of an epidemic outbreak (compare a hypothetical outbreak in the US vs. Guinea). That being said, I exclude all countries that are grouped higher than a low-income country by the World Bank since all three treatment countries are grouped as such. The control group is composed of the union of the two criteria mentioned.

Having established a solid control group necessarily leads to the question of whether the common trend assumption actually holds. There are several anecdotal arguments for this. Primarily, the history of the Ebola virus. 2014 was the first outbreak of Ebola in any of the affected countries. Additionally, it was the first epidemic outbreak of Ebola ever. Lastly, even though there has been research indicating that Westafrica should be considered potentially vulnerable, no public health official in Liberia knew of a potential danger neither the epidemic scale, as claimed by Nutt et al. (2015) in a 2015 New York Times (NYT) opinion piece.

Figure 5: Number of articles about Ebola in the NYT



Moreover, it is highly unlikely that the general public knew much about Ebola at all. Figure 5 shows the articles in the NYT mentioning Ebola at least once. Assuming that the NYT represents an (educated) population and reflects interests and priorities of a society, we clearly see that Ebola has not been a particular focus before the 2014 outbreak even though there have been several smaller outbreaks in the Congos or Gabon, amongst others, since 2000. Further,


google search query trends show a similar behaviour on large (see Fig. 4). All in all, I think this is strong evidence of why there has been no adjustment of health behaviour with respect to Ebola prior to the treatment thereby establishing the common trend assumption. Yet, a more thorough statistical analysis is paramount.

The following section provides a thorough statistical analysis whether the common trend assumptions can be believed to hold.

4.4.1 Event Study

Before we turn to performance of the DiD estimator, a closer look on the common trends assumption is imperative. Commonly, this is done by graphical inspection. Figure 6 shows how the averages of treatment and control group evolve around the intervention. Both are standardized around the control group at the year 2004.

Figure 6: Pre-trends



By eyeballing, we fail to see differences in pre-trends of treatment and control group. This finding gives confidence in the common trends assumption. Due to several treatment groups as well as several control variables, averages may be misleading suppressing important heterogeneity in the data. The common approach in the literature to solve the problem of multiple entries or treatment units are so called event studies, as pioneered by Bertrand et al. (2004) while Freyaldenhoven et al. (2018) and Borusyak and Jaravel (2017) provide recent discussion about pre-trend diagnostics.

The intuition is to simulate the same shock, holding controls equal, in every year before and after the actual shock at τ . If there are significant effects in every year prior to the intervention we would interpret this as a constant


difference between control and treatment group regardless of the intervention and the common trends assumption is unlikely to hold. The mathematical representation following Pischke (2005) can be seen in equation (25).

$$H_{it} = \sum_{j=-m}^q \beta_j Z_{it}(t = \tau + j) + \alpha_i + \gamma_t + \epsilon_{it} \quad (23)$$

where k is the time of the actual treatment, m representing leads, simulating treatment prior to the real treatment, and q lags, simulating treatment after the original one. In mathematical terms we need at least that $\beta_j = 0 \forall j < 0$ holds. While $\beta_j \neq 0 \forall j > 0$ is allowed since these can be interpreted as response coefficients over time such that $\sum_{j=\tau}^q \beta_j Z_{it}(t = \tau + j)$ represents the accumulated effect of the shock until q .

Figure 7 shows the results of exactly that. It shows the estimated coefficients for the Ebola "event" in 2014 with $-m$ equalling the year 2000 and $q = 2016$. Therefore, I include a total of 14 pre-treatment and 2 post-treatment periods. The estimation also includes a country-specific linear trend as it does in the baseline results which coefficient is not reported in the graph. Yet, the trend coefficient as well as more detailed results can be found in the Appendix table 16. Any year $10 \leq j \leq 14$ is grouped together as one estimand. By convention, the pre-treatment year $\tau - 1$ is used as standardization factor such that $\tau - 1 = 0$.

Figure 7: Event Study



Each y-line represents a different event before or after the outbreak τ in the form of a coefficient in the regression (25). The width of each estimate is the

95 % confidence interval. We observe a highly, statistical significant coefficient at time τ and declining estimation in magnitude for the following two periods which should not come as a surprise given that severity of the Virus dropped and international efforts became more efficient. Regardless, they still exhibit some statistical significance.

Within the pre-treatment periods are ten placebos that are statistically insignificant at the 5% level which is what would expect and gives confidence in the common trend assumption. However, when including a separate term for $t - 11$ for some robustness, this particular placebo becomes statistically significant. Since the following coefficients lose any significance immediately it appears unlikely for the placebo to have a lasting impact on the overall conclusion with regards to the common trends assumption.

When being more thorough in including the pre-event years by including all individually, the coefficient for $\tau - 11$ becomes significant. All others remain insignificant. This gives rise to some concern regarding parallel trends. Hereby it needs to notice that remaining coefficients and confidence barely change. Therefore, it appears to be a unrelated event rather than a systematic violation. Appendix figure 16 shows the results graphically. Freyaldenhoven et al. (2018) suggest to include an observable covariable that is highly correlated to the pre-trend and the outcome variable to solve pre-trends. If we are to believe that the statistical significance of $\tau - 11$ is a violation of parallel trends we would need to find a covariable that is unexpected before and after the year 2003. Despite the occurring proximity to a shock, I was unable to detect an event that could justify such a behaviour. Subsequently, I fail to include an appropriate control variable for $\tau - 11$.

Even given the concern raised just earlier, the common trend assumption seems to hold beyond a reasonable level of doubt. The following subsection turns towards the estimated results of the intervention.

4.4.2 Baseline results

As explained earlier, the regression to estimate the impact of the ebola outbreak on health contains the variable of interest, a linear country-specific trend and fixed effects for time and country.

The results of this baseline regression can be seen in table 6. Column I uses the prevalence of Ebola cases as a measure while Column II uses the number of Ebola articles.

In both cases, we can strongly statistically significant results. In column (I), an increase in the ratio of Ebola infected to the entire population by 1 %² leads to an approximate increase in the mortality rate by 97% keeping everything else constant. In other terms, there are an additional 97 out of 10000 adult

²Since I use the simple share of Ebola-infected individuals of the entire population in the regression, I divide the estimated results by 100 in order to receive results that are closer to the actual prevalence rate during the outbreak effectively equalling the per 10,000 definition.

Table 6: Baseline results

| Variables | (I) Log adult mortality rate | (II) |
|----------------------|---------------------------------|-------------------------|
| prev_ebola_new_cases | 0.9716*** (0.3169) | |
| log_ebola_articles | | 0.0203*** (0.00389) |
| time | -0.0236*** (0.00267) | -0.0238*** (0.00270) |
| Observations | 124,117 | 124,117 |
| R^2 | 0.633 | 0.635 |
| Number of id | 7,301 | 7,301 |
| Country-pair FE | Yes | Yes |
| Year FE | Yes | Yes |
| F-test | 39.60 | 69.58 |

Clustered standard errors in parentheses.

Clustering happens on the country level and consists of a total of 40 clusters.

*** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$

individuals to die before reaching the age of 60 or an average adult individual has a 0.97 % higher probability of dying before reaching the age of sixty due to Ebola.

The alternative specification for Ebola has a slightly different interpretation. We associate an 1% increase of Ebola-related articles and the particular countries with an increase of approximately 0.02% in mortality rates. In a standard interpretation this implies that an additional 203 out of 10,000 adult persons will die before reaching the age of 60.³ Maybe even more intuitive, the 1% increase in Ebola-related articles would be associated with the average person having a 2.03% higher probability of dying before turning 60.

On a first glance, these results seem to be quite separated from each other. However, one needs to keep in mind that the increased chance of dying prognosed by the estimated coefficients covers a 45-year-long time period since the individual is assumed to be 15 in the World Health Organization (2018) data structure.

Lastly, the linear, country-specific trend is statistically significant at all common levels of significance indicating the initial presence of a random walk.

When performing the regression of health, measured on a national basis, and Ebola, measured on a national level, with country-pair data, the coefficient

³Strictly speaking, this is not a correct transformation since the logarithm introducing the percentage interpretation also corrects for outliers and subsequently slightly altering the results. In that spirit, the given "level" interpretation is more of an approximation.

might be bias due to unequal weighting. For instance, if country A reports all health and trading data and at the same time country B all health but only one trading-pair data this might create artificial weights on this particular trading-pair. Subsequently, we would see a predominance of the effect in a certain set of countries-pairs. Therefore, I perform a regression of the same kind as in Table 6 but with data collapsed to the national level (Table 7). A similar coefficient and standard errors give confidence in the initial baseline results.

Table 7: Collapsed Baseline

| VARIABLES | (1) Prevalence rate | (2) Ebola Articles |
|--------------|-------------------------|-------------------------|
| col_prev | 1.296** (0.597) | |
| col_articles | | 0.0217*** (0.00554) |
| time | -0.0229*** (0.00250) | -0.0231*** (0.00253) |
| Observations | 680 | 680 |
| R^2 | 0.628 | 0.629 |
| Country FE | Yes | Yes |
| Year FE | Yes | Yes |
| F-statistic | 42.04 | 47.37 |
| No. clusters | 40 | 40 |

Robust standard errors in parentheses

*** p<0.01, ** p<0.05, * p<0.1

When comparing Table 6 to Table 7, we observe plentiful similarities. Statistical explanatory power is almost equal with the exception of the case prevalence being significant only at the 5 % level. The coefficient of the case prevalence itself is slightly larger but well within the range of estimates following in the next section. The alternative specification does not differ in terms of statistical significance and the coefficient changes only at the third digit. Overall, the results give the impression that the potential weighting bias does not appear to be severe in size. Therefore, I proceed by using the country-pair specification. Yet, the lack of control variables included imposes a threat to the consistency of the OLS results known as the omitted variable bias. The following subsection will deal with this problem.

4.4.3 Control Variables

In the framework of DiD, we care about omitted variables for mainly two reasons. First, a control variable that correlates with the treatment variable causing

an inconsistent estimate of the treatment effect. Secondly, in existence of unit-specific trends the common trend assumption could be violated. By including a control variable that captures precisely these unit-specific trends, the common trend assumption could be restored. While the second concern doesn't not seem to pose any particular threat to the validity, at least on the basis of the event study performed earlier, the first concern might be problematic.

Unsurprisingly, finding and including a cohesive list of possible confounders is not an easy task. A vast body of literature trying to determine predictors of mortality nicely collected with different focus by Cutler et al. (2006), Soares (2007) and Arcaya et al. (2015) proves this point. Additionally, many determinants of health inequalities happen on an individual level. Examples include but do not constrain to stress, social inclusion and maternal stress during pregnancy (Thoits (2010), Cohen (2004) and Almond and Currie (2011)). These are hard to measure, even harder to aggregate and overall more likely to explain within-country variations rather than variations between countries.

Notwithstanding, there are some aggregated measures that can help to reduce the risk of inconsistent estimated due to omitted variable bias. Cutler et al. (2006), for instance, argue that urbanization initially increases mortality rates due to the facilitated spread of diseases. In arguing that public health should be considered as a determinante, they follow Preston (1975). The key argument is that higher income alone does not suffice to explain the historic reduction since countries would then follow the preston curve which is not matched by the data. Instead, public investments in sanitation, filtering water as well as setting up vaccination campaigns was essential. Another point by Cutler et al. (2006) is improved nourishment. Intuitively, a better-fed erson has a lower propensity to get sick and at the same a higher likelihood to recover faster.

Some more potential confounders are found in Marmot (2005). The authors evaluate that wealth and inequality are important factors to consider when investigating health inequalities. While the data availability for inequality in 2014/2015 is not perfect yet and therefore not ready to be included, wealth data can be included. More recently, the internet has changed health behaviour of patients and doctors significantly (Cook et al. (2008)). Therefore, I include the percent of internet accesses as an additional control variable.

Lastly, I capture any confounding effect of the most pressing diseases by including HIV prevalence, Tuberculosis cases and some others. Hereby, I follow the *Global Burden of Disease Study* by Lozano et al. (2012). Further, I considered including education but a growing amount of literature fails to confirm education as a determinant for adult health outcomes (Clark and Royer (2013) or Meghir et al. (2018)).

Generally, I organize the adding of control variable table 8 threepartly. First, control variables following the established literature are included (columns I and II). Columns III and IV further contain HIV prevalence, tuberculosis and malaria as some of the severest diseases in Sub-Saharan Africa (Lozano et al. (2012)). Furthermore, the access to medical treatment and health service in general for these diseases has been greatly limited during the 2014 Ebola outbreak, according to Parpia et al. (2016). These effects on mortality should be

seen as a indirect effect caused by the intervention and by controlling for such we receive a more precise estimate of the direct impact. The two remaining, right-sided columns include further diseases not known to have been influenced by Ebola and yet might coincidentally be correlated with the treatment variable. Odd columns have prevalence of Ebola cases as measurement while even columns incorporate the article measurement.

In column I and II of table 8, we observe that the estimated treatment effect increases in a sense that treatment has a more severe impact on mortality while statistical significance has not changed with regards to the level of significance. Now, we associate an increase in of the Ebola affected population relative to the overall population by 1% with an individual's increased likelihood of dying before the age of 60 of approximately 1.73%. Respectively, 10% more articles on Ebola is associated with 0.25% higher probability of dying before the age of 60. Simultaneously, wealth, urbanization and fatalities appear to be confounders impacting the mortality rate. Wealth emerges as the most significant control variable not only by statistical but also economic significance. According to the estimate, higher wealth leads to lower mortality. Urbanization and fatalities on the other hand, are economically and statistically less significant but positively connected to mortality, i.e. that higher urbanization and more fatalities yield a higher likelihood of dying before the age of 60. Even though they are exhibit an intuitive sign, we should be careful when interpreting the coefficients. Cutler et al. (2006) and Gonzalez-Torres and Esposito (2017) point out that any of these three variables suffers from biased results due to reverse causality or omitted variable bias. Incorporating endogenous control variables can be potentially harmful, however. If an endogenous control and the exogenous treatment were correlated the estimated β_{treat} would be

$$plim\hat{\beta}_{treat} = \beta_{treat} + \gamma \frac{Cov(X^*, Z)}{Var(X_{treat})}$$

where Z is an unobserved factor and

$$X^* = [I - X_{cont}(X'_{cont}X_{cont})^{-1}X'_{cont}]X_{treat}$$

if now $Cov(X_{treat}, X_{cont}) \neq 0$ and $Cov(Z, X_{cont}) \neq 0$ our results are biased. As a result, any treatment evaluation relies on the assumption of no selection bias conditional on observables (CIA). After having established the "surprise" nature of the shock earlier, it seems likely that the CIA assumption holds or otherwise would not have been a "surprise" shock.

Columns III and IV include with Malaria prevalence per 1000 persons, HIV prevalence and Tuberculosis prevalence per 10000 three relatively common diseases in general that are also related to the 2014 Ebola outbreak (Parpia et al. (2016)). Anemia itself is a considerable burden and according to Ehrhardt et al. (2006) highly connected to malnutrition. Therefore, it captures potential effects

Table 8: Control results

| | (I) | (II) | (III) | (IV) | (V) | (VI) |
|------------------------|--------------------------|-------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| | Log adult mortality rate | | | | | |
| prev_ebola_new_cases | 1.731*** (0.5285) | | 1.15*** (0.3013) | | 1.122*** (0.2942) | |
| log_ebola_articles | | 0.0253*** (0.00523) | | 0.0147*** (0.00493) | | 0.0141*** (0.00502) |
| percent_urban | 0.0221** (0.00958) | 0.0230** (0.00963) | 0.0174** (0.00810) | 0.0182** (0.00830) | 0.0175** (0.00808) | 0.0183** (0.00830) |
| log_health | 0.00926 (0.0446) | 0.0158 (0.0435) | -0.0396 (0.0486) | -0.0353 (0.0483) | -0.0402 (0.0483) | -0.0360 (0.0480) |
| percent_internet | -0.00368 (0.00339) | -0.00414 (0.00348) | -0.00325 (0.00286) | -0.00348 (0.00293) | -0.00342 (0.00286) | -0.00361 (0.00292) |
| log_gdp_p_c | -0.332*** (0.110) | -0.322*** (0.110) | -0.255** (0.111) | -0.253** (0.110) | -0.250** (0.112) | -0.249** (0.111) |
| gdp_p_c_growth | 0.00109 (0.00107) | 0.000966 (0.00107) | 0.000241 (0.000907) | 0.000184 (0.000906) | 0.000243 (0.000904) | 0.000189 (0.000901) |
| log_fatalities | 0.00759* (0.00421) | 0.00795* (0.00422) | 0.00476 (0.00372) | 0.00503 (0.00372) | 0.00471 (0.00371) | 0.00497 (0.00370) |
| time | -0.0254*** (0.00531) | -0.0261*** (0.00540) | -0.0132** (0.00545) | -0.0139** (0.00572) | -0.0130** (0.00547) | -0.0138** (0.00576) |
| prev_HIV | | | -0.000812 (0.000636) | -0.000869 (0.000630) | -0.000814 (0.000634) | -0.000869 (0.000628) |
| tuberculosis_cases | | | 0.000246** (0.000121) | 0.000254** (0.000121) | 0.000250** (0.000120) | 0.000257** (0.000120) |
| log_anemia | | | 0.996*** (0.300) | 0.974*** (0.307) | 0.993*** (0.298) | 0.973*** (0.305) |
| malaria_p1000 | | | -0.000103* (5.46e-05) | -0.000102* (5.45e-05) | -0.000113* (5.71e-05) | -0.000111* (5.72e-05) |
| CVD_cancer_diab | | | | | 0.000121 (0.000129) | 0.000103 (0.000130) |
| diarrhea_treat_percent | | | | | -5.26e-05 (7.19e-05) | -4.42e-05 (7.44e-05) |
| Observations | 82,762 | 82,762 | 82,762 | 82,762 | 82,762 | 82,762 |
| R ² | 0.723 | 0.726 | 0.790 | 0.790 | 0.791 | 0.791 |
| Number of id | 6,471 | 6,471 | 6,471 | 6,471 | 6,471 | 6,471 |
| State and year FE | Yes | Yes | Yes | Yes | Yes | Yes |
| F-test | 14.34 | 33.22 | 17.90 | 51.36 | 18.26 | 52.98 |

Cluster-robust standard errors in parentheses. The data is clustered on the country level

Year and country fixed effects are included in all regressions

*** p<0.01, ** p<0.05, * p<0.1

on mortality by insufficient nourishment and Anemia.

Statistical significant estimated can be recognized for Malaria, Tuberculosis and Anemia. With the latter two exposing a strong, positive effect on mortality, reversly likely decreasing life expectancy. At the same time, the obtained coefficient for treatment measured in prevalence of Ebola cases drops significantly in economic magnitude to almost pre-control level. Now, an increase in the Ebola-Population ratio by 1% should lead to 115 more deaths in each 10,000 people. This is equivalent to an increased risk of an individual dying before 60 by 1.15%. The story for the second measure, Ebola articles, is similar with the only difference being that the drop in economic magnitude is steeper going beyond pre-control levels. 10% more articles are now causing mortality to increase by approximately 0.147% .

The last two columns, V and VI, include a measure for cardiovascular diseases, cancer and diabetes as well as another measure for diarrhea. None of these disease have been linked to any Ebola outbreak so we should expect no economic and statistical significance except for a coincidental correlation. Columns V and VI exhibit exactly these characteristics. Both new control variables are statistically insignificant. Besides, both estimated treatment coefficients are close to equal to the previous columns in economic magnitude and statistical significance. The relatively constant estimates in magnitude and significance lend further trust in the credibility of the estimates.

Since the data offers a time series component, a look at the development of the shock over time can be rewarding. Subsection ?? does that.

ADD: PREFERRED SPECIFICATION

4.4.4 Impulse Response Functions

Economists have long been interested in the temporal development of shocks. Blanchard and Quah (1988) started estimating dynamic effects in macroeconomic VAR models by extrapolating into future time periods with a previously determined model. Building on a similar idea, Jordà (2005) developed impulse response functions based on local projections. Hereby, a researcher runs a distinct regression on every desired future period of outcome.

Clearly, there are not many periods following up to 2014 in my dataset. More precisely, only 2015 and 2016 data is included so that the local projections are short in length. Figure 8 shows the two impulse response function for regressions based on the specification in table 6, ignoring any control variables. The left graph uses Ebola prevalence as a measure while the right graph employs the number of Ebola-related articles as measurement.

Unsurprisingly, both graphs draw a similar picture. The effect of the Ebola outbreak fades out with becoming economically close to zero already in 2015, the first year after the outbreak in the prevalence specification⁴. The decreasing statistical significance in the same period supports the picture of a vanishing

⁴Time 2 in the graph




Figure 8: This figure shows the collection of local projections impulse response functions following Jordà (2005) without including any control variables. The left half has the prevalence of Ebola cases as the measure for Ebola. On the right side, the measure for Ebola is the number of Ebola-related articles in the NYT. The maroon line marks the estimated coefficients while the shaded areas indicates the 95% confidence intervals.

effect over time, with that effect being stronger in the case of prevalence specification. When using articles, the results suggests at in the first past the outbreak there might be some ongoing health-damaging effects since its coefficient is positive and statistically significant at the 95% level. The unclarity regarding the follow-up year can be founded in intuition since there are several effects occurring simultaneously. First, the Ebola crisis is still impacting the countries heavily, even though at declining infection and fatality rates (CITATION NEEDED). At the same time, international efforts to contain the outbreak show signs of success (CITATION NEEDED).

In either specification, it becomes evident that in 2016 the impact is life-enhancing. Mortality rates in the treatment group drop significantly, in the economic and statistical sense. This result is very intuitive. In 2016, the WHO declared that all three countries can be considered Ebola-free (Organization et al. (2016)). Significant, positive results for continuing effects in 2016 would capture long-term effects for longer than 2 years. Although not impossible, most long-term effects of Ebola confirmed by researchers last up to two years but hardly longer (Clark et al. (2015) and Rowe et al. (1999)). Contesting theories such that an increased mortality rate of weekend health workers leads to higher overall mortality rate since it lowers quality and quantity of the provided health care, as carefully outlined in Evans et al. (2015) does not appear to be a prevailing force in the direct aftermath.

The observed negative on the other hand can be explained by two potential factors. Firstly, international investments in health infrastructure and increased development aid could lower post-Ebola mortality rates. There is some evidence suggesting that official development aid increases in the aftermath of a natural disaster, though small in size (Becerra et al. (2014)).

In contrast to this, there may simply be mean reversion as considered a potential problem in the context of health convergence investigated by Jayachandran and Lleras-Muney (2009).

If it was the a reason in the same category as the earlier explanation rather than the latter explanation, we would expect to see a level shift in future health outcomes since it likely provides benefits beyond the mean. Mean reversion does not exhibit the same benefits. Future reasearch could exploit this pattern. Further, undetected in my impulse response function are any sorts of long-term effects that firstly occur in the years after the considered horizons. An example could be long-term effects in the setting of the fetal origins hypothesis (Almond and Currie (2011)). If in-utero malnutrition or stress trigger worse health and education outcomes, children of the effected mothers would still suffer consequences.

Adding control variables following the preferred specification of column (III) and (IV) of table 8 only confirms the overall picture. As can be seen in figure 9, the trend approximately equals the trend in the previous graphs. If anything, we observe some difference in the behaviour of the second post-intervention estimations. The estimates lose some their statistical significance but are similar in economic magnitude. The post-intervention year $\tau + 1$ does not appear to bear any statistical significance anymore.




Figure 9: Figure 9 is the collection of local projections impulse response functions following Jordà (2005) with including the set of control variables as specified in column III and IV of table 8. The left half has the prevalence of Ebola cases as the measure for Ebola. On the right side, the measure for Ebola is the number of Ebola-related articles in the NYT. The maroon line marks the estimated coefficients while the shaded areas indicates the 95% confidence intervals.

Before turning to the second stage results, there is need to examine the standard errors of the DiD. Subsection ??? does that.

4.4.5 Biased Standard Errors

In economics, clustered data is commonly used for empirical estimation. As already stated in work such as Moulton et al. (1990), this can cause problematic

consequences for inference if there is correlation within a cluster. As a result, many empirical studies use cluster robust variance estimator (CVRE).

In the DiD framework, there are three main problems arising when using CVRE. Primarily and widely discussed after the seminal work by Bertrand et al. (2004), is the issue of few clusters. Secondly, Conley and Taber (2011) note that the standard errors will be severely biased if the DiD estimator lacks sufficient treated clusters. The last condition demands similar amount of datapoints for each cluster. Carter et al. (2017) and MacKinnon and Webb (2017) show theoretical and practical simulation on this condition. In the following paragraphs, I will expound the relevance of these concerns for my investigation.

The first condition can be rephrased as a requirement that the number of clusters goes to infinity in order to ensure consistency of the estimator. If this condition is only marginally satisfied, the DiD tends to over-reject and t-statistics grow artificially large. The main mechanism at work is serial correlation in the error term. This is in large parts due to the intervention variable itself for it being a dummy variable (Bertrand et al. (2004) or Donald and Lang (2007)). Although there is no clear rule of what "marginally satisfied" means, results by Cameron et al. (2008) suggest that 40 clusters are enough to suffice this condition, given a balanced panel.

The baseline regression results should not expose severely biased standard errors in this respect since the cluster number of 40 seems high enough. However, when dealing with the results containing the control variables too this could prove an issue. With only 34 clusters, the model might suffer from over-rejection. There are several suggestions when dealing with this problem. For instance, a cluster-by-group approach as proposed in Bertrand et al. (2004) or the wild cluster bootstrap following Cameron et al. (2008).

According to Conley and Taber (2011) the same difficulty arises when the overall number of clusters is sufficiently large, but the number of treated units small. They show that the noise biasing the estimated fixed-effects regression yields consistent estimates only decreases with number of treated units but not with the overall number of clusters. While the former solution proposals are still valid, they propose a special form of randomization inference. While they do state a clear cut-off when the number of treated units is too small, they show that under some circumstances even as much as ten treated clusters are not sufficient to have unbiased standard errors with the standard procedure. Subsequently, having three treated clusters, as this study does, seems particularly vulnerable to this reasoning.

In the light of recent research most of these solution attempts have been shown to yield biased results themselves, at least in a practitioner's world. MacKinnon and Webb (2017) show that standard procedures such as Bertrand et al. (2004) or Cameron et al. (2008) fail when presented with unequally sized clusters or clusters are too few in numbers. They further prove that restricted wild cluster bootstrap underrejects for samples smaller than 4 but the unrestricted wild cluster bootstrap overrejects. They conclude that the true standard errors should fall within that interval. In a follow-up study, MacKinnon and Webb (2018) propose sub-clustering to narrow down the margin of the interval.

This is, as the previous point, relevant for this study. Since clustering is assumed to happen at the state level but trade is measured with country pairs each cluster has a different number of observations. For example, the Chad has an amount of 5899 country pair observations making up 4.63% of the total sample. The South Sudan on the other hand, has a total of 1241 observations with accumulates to 0.97 % (both, however, are part of the control group). That means, the size of the Chad is almost five times the size of South Sudan's. On average, treated cluster in this study incorporate 3042 observations in contrast to 3358 for the untreated. The ratio of treated to untreated is 1.1 which should introduce, if any, a small amplifying bias on wildly bootstrapped standard errors.

Out of the three potential causes for biased standard errors, at least one - few treated clusters - is highly likely to affect the estimated results. While the procedure by Conley and Taber (2011) suffices for few treated clusters, it fails if the slightly unequal cluster sizes turn out to be relevant. Therefore, I stick to the procedure suggested by Cameron et al. (2008) and improved by MacKinnon and Webb (2018) which can account for this. But before turning to the results, I believe the terms of unrestricted and restricted cluster bootstrap deserve some explanation.

Generally, the bootstrap is a resampling method to evaluate the likelihood of reaching the same result as in the original estimation with a subset of data. In more detail, the researcher draws, with replacement, a set of random number from the original dataset until she reaches the desired number of G bootstrap samples. Next, one has to regress for each bootstrap sample and find the corresponding t-statistic. Lastly, the original estimation can be evaluated against the distribution of bootstrapped results. While cluster bootstrapping, as described in this paragraph, is a powerful tool MacKinnon and Webb (2017) show that in the presences of few treated clusters it yields misleading results. That is because with very few treatment observations many bootstrap samples will have zero for every treatment observation.

Wild cluster bootstrap is similar to this but solves this problem. Hereby, the original regression is calculated, yielding the standard cluster-robust t-statistic t_j for $\beta_j = 0$. In Cameron et al. (2008), the restricted wild cluster approach, the next step is to regress again given that $\beta_j = 0$. This gives the new estimates $\tilde{\beta}$ and \tilde{u} . Now, for each bootstrap sample one regresses

$$\mathbf{y}^b = \mathbf{X}\tilde{\beta} + \mathbf{v}\tilde{\mathbf{u}} \quad (24)$$

where \mathbf{v} represents an augmented weight vector with the length of the number of clusters. The weights are drawn from a Rademacher distribution. We obtain the estimates $\hat{\beta}^b$ and $\hat{\mathbf{u}}^b$. For each bootstrap sample the t-statistic t_j^b for the hypothesis $\hat{\beta}^b = \tilde{\beta}$ can be computed. Lastly, Cameron et al. (2008) recommend calculating new p-values to by comparing the original t-statistic to the distribution of t_j^b .

MacKinnon and Webb (2017) explain that the unrestricted wild cluster bootstraps is essentially equal to the above procedure with the only difference being

that $\tilde{\beta}$ is simply being the set to equal $\hat{\beta}$. $\hat{\beta}$ is the originally estimated coefficient.

And yet, with very few treated clusters even a wild bootstrap can fail. In short, if the original error term produces large t-statistics, the Rademacher weights with its bimodal properties will create even bigger bootstrap t-statistics.⁵ As a rule of thumb, they suggest that studies with fewer than four treated clusters will show misleading wild cluster bootstrap standard errors.

To solve this, MacKinnon and Webb (2018) suggest to use sub-cluster to reduce the proportions of the error. Djogbenou et al. (2018) ground the wild bootstrap theoretically when discovering that the results of sub-clustering is asymptotically valid even when there is intra-cluster correlation. Thereby, I follow the implementation as in Roodman et al. (2019) by using their Stata package **bootstrap**.

Every estimation employs 1499 bootstrap replication and is based on the baseline estimation as in Table 6. Table 9 and 10 report the confidence intervals at the 95% of significance. Table 9 does not include any control variables.

Table 9 confirms most of the findings explored earlier. Firstly, we do observe major changes across different wild cluster bootstraps and cluster specification. For instance in column (II) where we observe the expected behaviour. On the one side, the hypothesis of no effects of the Ebola variable on health outcomes can not be rejected at any common level of significance, however by a close margin. On the other side, the unrestricted wild cluster bootstrap shows, basically, the same confidence intervals and p-value as the original estimation. When using sub-clusters the values converge strongly. Now, both estimates are significant on the 1% level and show very similar confidence intervals to each other but also to the original estimates.

Column I is behaving differently. Unexpectedly, the restricted wild cluster bootstrap exhibits a long left-side tail for the confidence interval such that the estimated sign now turns negative.

?? WHY ???

When clustering the bootstrap results on a country-pair level, the restricted bootstrap takes on the expected form and converges to the unrestricted bootstrap. The level of significance can now be of the estimate around the 10% level.

The results for the article measurement of Ebola appear to confirm the initial results strengthening the confidence in these. The results for the case prevalence rate are not as convincing but nevertheless point into the same direction.

The missing step now is to find out if the results with control variables offer the same robustness. As already shown earlier, the estimation including control variable has moderately fewer clusters. In fact, there are 6 fewer control clusters now. Theoretically, this should amplify errors in both bootstrap methods. We would therefore expect higher p-values (restricted) and lower p-values (unrestricted) than in Table 9, although it might not be of relevant magnitude.

10 shows the predicted behaviour. The restricted bootstrap underrejects while

⁵see MacKinnon and Webb (2017) for the full proof

Table 9: Wild cluster bootstrap

| | (I) | | (II) | |
|---|-----------------|-----------------|-----------------|-------------------|
| Treatment group | Three countries | | Three countries | |
| Treatment variable | Case prevalence | | Ebola articles | |
| Estimate | 0.9716 | | 0.02 | |
| Cluster robust s.e. | 0.3169 | | 0.004 | |
| t-statistic | 3.07 | | 5.21 | |
| P-values & CI | P value | CI | P value | CI |
| Initial results | 0.004 | [0.331, 1.613] | 0.000 | [0.012, 0.028] |
| Bootstrap by country, restricted | 0.105 | [-631.6, 24.2] | 0.1054 | [-.1698, .2974] |
| Bootstrap by country, unrestricted | 0.28 | [-.461, 2.404] | 0.0000 | [.01224, .02828] |
| Bootstrap by country-pair, restricted | 0.0856 | [-1.649, 5.502] | 0.009 | [.009949, .03193] |
| Bootstrap by country-pair, unrestricted | 0.1381 | [-.5862, 2.529] | 0.000 | [0.012, 0.028] |

the unrestricted bootstrap overrejects. Column (I) shows the restricted bootstrap indicating statistically insignificant results while the unrestricted claims both to be statistically significant on the 1% level. Sub-clusters tend to the same coconvergence as in Table 9. Especially the restricted wild cluster bootstrap converges towards statistical significance. The unrestricted estimate remains very constant and is still highly significant. Here as above, the article estimation seem to be very robust and unaffected by the few treated clusters.

Table 10: Wild cluster bootstrap with controls

| | (I) | | (II) | |
|---|-----------------|-----------------|-----------------|-----------------|
| Treatment group | Three countries | | Three countries | |
| Treatment variable | Case prevalence | | Ebola articles | |
| Estimate | 1.15 | | 0.015 | |
| Cluster robust s.e. | 0.301 | | 0.005 | |
| t-statistic | 3.82 | | 2.98 | |
| P-values & CI | P value | CI | P value | CI |
| Initial results | 0.001 | [0.537, 1.763] | 0.005 | [0.005, 0.025] |
| Bootstrap by country, restricted | 0.165 | [-23.98, 16.41] | 0.121 | [-0.073, 0.089] |
| Bootstrap by country, unrestricted | 0.001 | [0.538, 1.761] | 0.003 | [0.005, 0.024] |
| Bootstrap by country-pair, restricted | 0.148 | [-1.619, 4.399] | 0.065 | [-0.003, 0.029] |
| Bootstrap by country-pair, unrestricted | 0.003 | [0.442, 1.857] | 0.003 | [0.005, 0.024] |

Overall, the bootstrap results seem to confirm the results of the cluster-robust variance matrix estimator. Therefore, we can now turn towards the second stage of the estimation.

4.5 Second Stage

After having established, a valid difference-in-difference set-up and relevance for the coefficient of interest beyond a reasonable scepticism, we can see how the estimated health coefficients influence trade outcomes. Namely, I will focus on exports, imports as well as trade balance.

According to the theoretical simulation drawn out in section ???, we have clear expectations about the coefficient signs and an indication about economic as well as statistical relevance. For exports, we expect a negative sign and likely statistical significance. The same pattern is supposed to hold for the trade balance. Imports should follow a different pattern. While a negative sign on impact is expected, this should turn positive in the second post-shock period. In the first year after the shock, we expect still a negative sign but a smaller coefficient. Since the real data only cover the first three periods of the shock, we expect a negative sign. Studies including a larger time horizon are expected to find a positive sign for a contemporaneous regression. Given the generally smaller deviation from zero in the simulation, the effect might be undistinguishable from zero. Therefore, doubt about statistical significance are reasonable.

4.5.1 Baseline

I start to draw out the second stage by presenting the regression equation following an instrumental variable design.

$$Y_{ijt} = \beta \mathbf{H}_{it} + X'_{it}\eta + \alpha_{ij} + \zeta_t + \epsilon_{it} \quad (25)$$

with

$$\mathbf{H}_{it} = \beta Z_{it} + Q'_{it}\nu + X'_{it}\eta + \pi_{it} + \alpha_i + \zeta_t + \epsilon_{it} \quad (26)$$

being equal to equation (22) of the previous section. i indexes the country of origin and j the corresponding trading partner. To fix ideas, i can be any of the 40 countries of control or treatment group while j is any country trading with i . t indexes years. $Q'_{it}\nu$ represents the control variables of the first stage while $X'_{it}\eta$ represents those of the second stage. As in the previous regression, π_{it} represents a country-pair-specific linear trend across time. α_{ij} accounts for country-pair specific fixed effects with ζ_t controlling for time fixed effects.

An intuitive second stage result without any control variables, can be found in Table 11. While the first two columns use exports as the dependent variable, the middle columns use imports. The two columns on the right regress on the trade balance. All three variable are measured in constant 2010 Dollars. A natural logarithmic transformation to exports and imports has been applied in order to ease interpretation.

When taking a look at exports, we find strong economic and statistical relevance of health as a determinant. We associate an increase in the mortality rate by one percent with an decrease in exports by about three percent. This is independent of the instrument used. Having three treated clusters is subject

Table 11: Second Stage Baseline

| VARIABLES | (1) Exports | (2) Exports | (3) Imports | (4) Imports | (5) Trade Balance | (6) Trade Balance |
|-------------------------|----------------------|----------------------|--------------------|--------------------|----------------------|----------------------|
| log_adult_mort | -3.203*** (0.677) | -3.179*** (0.675) | 0.0591 (0.0499) | 0.0649 (0.0494) | 11.37 (28.53) | 11.28 (28.68) |
| Observations | 57,794 | 57,794 | 64,203 | 64,203 | 84,288 | 84,288 |
| Country-pairs | 6,365 | 6,365 | 6,076 | 6,076 | 7,232 | 7,232 |
| Instrument | Prevalence | Articles | Prevalence | Articles | Prevalence | Articles |
| FE | Yes | Yes | Yes | Yes | Yes | Yes |
| F-statistic first stage | 34.64 | 47.49 | 41.77 | 58.36 | 39.81 | 52.08 |
| No. of clusters | 40 | 40 | 40 | 40 | 40 | 40 |

Robust standard errors in parentheses

*** p<0.01, ** p<0.05, * p<0.1

to them same concern voice in section ??????. The unrestricted as well as the restricted wild clustered bootstrap errors show highly significant results with 95% confidence intervals between approximately -4.3 and -1.9 for both cases. That leaves us with good confidence in the economic and statistical relevance of health in determining exports.⁶


When we turn to imports, we find the unexpected, positive sign. Economically, an increase in mortality rates by one percent would be expected to yield an increase in imports by about 0.06%. A t-statistic of about 1 in both specifications confirms our initial concerns regarding the relevance of health outcomes for import behaviour.

With respect to incomes, the simple model prognosticated a reduction in income due to the overall loss in output allowing less consumption and investment with in return implies less imports. These mechanism does not seem to be dominant. Agnostically surprising, the trade balance does not follow the trend of exports at all. On the contrary, the estimated sign is positive and the estimation fails reject to null of no statistical significance. The effect seems to be similar to the effect on imports, instead. The most intuitive answer to this would be that imports are greater in value terms than exports. The theoretical simulation is an exchange economy in contrast to the real economy where real prices matter. And indeed, the data exhibits an inequality as can be seen in Figure 10.

Here, every blue dot represents a country-pair's value of exports and imports. The red line marks the 45 degree. If imports and exports were equal we would expect the cloud to be symmetric above and below the red line. However, the part below the red line seems swollen indicating imports being larger than exports for the employed sample. The green line shows a more thorough approach to answer the same question. It is a simple regression of imports on exports. Since the slope of the green line is smaller than of the red line, we can conclude that exports are less in size than imports for our sample.

⁶More results can be obtained from the author

Figure 10: Export-Imports Scatter



4.5.2 Control variables

As already suggested by the semi-structural equation derived in section ??, control variables should be taken into account. Before including the variables as proposed by that equation, I consider only to include output. Since, as derived in section ??, the effect should work via production, we would expect any health effects on trade to diminish economically as statistically once output itself is included.

Table 12 shows these predictions are only partially correct. Indeed, coefficients as well as t-statistics are closer to zero in comparison to Table 11. That indicates that a significant share of the overall works via the production. For exports, the estimated share of production of the overall effect is approximately 24%. With regards to imports, 90% of the estimated coefficient in Table 11 are dropped. Given that the original estimate was already statistically not significant, a cautious interpretation is needed. Albeit, it poses a intriguing argument for the relevance of production on importing behaviour.

4.5.3 Impulse response function

Table 12: Second Stage Output

| VARIABLES | (1) Exports | (2) Imports | (3) Trade Balance | (4) GDP |
|-------------------------|---------------------|---------------------|----------------------|----------------------|
| log_adult_mort | -2.443** (1.210) | 0.00545 (0.0675) | 47.64** (22.70) | -0.893*** (0.140) |
| log_gdp_p_c | 0.849 (0.836) | -0.0541 (0.0650) | 37.61 (44.07) | |
| Observations | 56,188 | 62,350 | 81,872 | 119,421 |
| Number of id | 6,184 | 5,893 | 7,022 | 7,085 |
| Instrument | Prevalence | Prevalence | Prevalence | Prevalence |
| FE | Yes | Yes | Yes | Yes |
| F-statistic first stage | 493.4 | 493.4 | 493.4 | 493.4 |
| No. of clusters | 38 | 38 | 38 | 38 |

Robust standard errors in parentheses

*** p<0.01, ** p<0.05, * p<0.1

Table 13: Second Stage Control Variables

| Dependent Variable | (1) Exports | (2) Exports | (3) Imports | (4) Imports | (5) Trade Balance | (6) Trade Balance |
|-------------------------|----------------------|----------------------|------------------------|------------------------|----------------------|----------------------|
| log_adult_mort | -3.205*** (0.886) | -3.205*** (0.886) | 0.274 (0.240) | 0.274 (0.240) | 56.21 (55.85) | 56.21 (55.85) |
| log_pop | -0.511 (0.442) | -0.511 (0.442) | 0.0692 (0.160) | 0.0692 (0.160) | -2.092 (64.10) | -2.092 (64.10) |
| lag_lcap | 0.277* (0.160) | 0.277* (0.160) | 0.0312 (0.0400) | 0.0312 (0.0400) | 6.842 (9.471) | 6.842 (9.471) |
| tariff | 0.0225 (0.0235) | 0.0225 (0.0235) | -0.000835 (0.00212) | -0.000835 (0.00212) | -4.494 (2.939) | -4.494 (2.939) |
| Instrument | Prevalence | Articles | Prevalence | Articles | Prevalence | Articles |
| Observations | 34,146 | 34,146 | 37,318 | 37,318 | 49,332 | 49,332 |
| Number of id | 5,168 | 5,168 | 5,062 | 5,062 | 6,136 | 6,136 |
| FE | Yes | Yes | Yes | Yes | Yes | Yes |
| F-statistic first stage | 5455 | 5455 | 4708 | 4708 | 4155 | 4155 |
| No. clusters | 35 | 35 | 35 | 35 | 35 | 35 |

Robust standard errors in parentheses

*** p<0.01, ** p<0.05, * p<0.1

Table 14: Second Stage Control Variables II

| VARIABLES | (1) Exports | (2) Imports | (3) Trade Balance |
|-------------------------|-----------------------|-----------------------|----------------------|
| log_adult_mort | -1.887* (1.078) | -0.00754 (0.185) | 85.53 (63.04) |
| log_pop | -0.224 (1.464) | 0.307 (0.326) | -125.1 (127.2) |
| lag_lcap | 0.246 (0.180) | -0.0327 (0.0481) | -4.300 (11.66) |
| tariff | -0.00139 (0.0130) | -0.00294 (0.00223) | -4.057** (1.885) |
| log_gdp_p_c | 0.000770 (0.597) | 0.131 (0.139) | 178.7*** (63.24) |
| gdp_p_c_growth | 0.00831 (0.00683) | -0.00106 (0.00226) | -1.309*** (0.452) |
| log_fatalities | -0.0123 (0.0218) | 0.00846 (0.00656) | -0.362 (1.468) |
| percent_internet | -0.0352** (0.0165) | -0.00271 (0.00375) | -2.491* (1.328) |
| percent_urban | 0.119*** (0.0381) | -0.0170 (0.0106) | 7.868 (5.630) |
| Observations | 24,944 | 27,333 | 35,763 |
| Number of id | 4,446 | 4,395 | 5,318 |
| Instrument | Prevalence | Prevalence | Prevalence |
| FE | Yes | Yes | Yes |
| F-statistic first stage | 13.28 | 13.28 | 13.28 |
| No. clusters | 36 | 36 | 36 |

Robust standard errors in parentheses

*** p<0.01, ** p<0.05, * p<0.1




Figure 11: This figure shows the collection of local projections impulse response functions following Jordà (2005) without including any control variables. The left half has the prevalence of Ebola cases as the measure for Ebola. On the right side, the measure for Ebola is the number of Ebola-related articles in the NYT. The maroon line marks the estimated coefficients while the shaded areas indicates the 95% confidence intervals.




Figure 12: This figure shows the collection of local projections impulse response functions following Jordà (2005) without including any control variables. The left half has the prevalence of Ebola cases as the measure for Ebola. On the right side, the measure for Ebola is the number of Ebola-related articles in the NYT. The maroon line marks the estimated coefficients while the shaded areas indicates the 95% confidence intervals.

References

- ACEMOGLU, D. AND S. JOHNSON (2007): “Disease and development: the effect of life expectancy on economic growth,” *Journal of political Economy*, 115, 925–985.
- ADJEMIAN, S., H. BASTANI, M. JUILLARD, F. MIHOUBI, G. PERENDIA,




Figure 13: This figure shows the collection of local projections impulse response functions following Jordà (2005) without including any control variables. The left half has the prevalence of Ebola cases as the measure for Ebola. On the right side, the measure for Ebola is the number of Ebola-related articles in the NYT. The maroon line marks the estimated coefficients while the shaded areas indicates the 95% confidence intervals.

- M. RATTO, AND S. VILLEMOT (2011): “Dynare: Reference manual, version 4,” .
- ALMOND, D. AND J. CURRIE (2011): “Killing me softly: The fetal origins hypothesis,” *Journal of economic perspectives*, 25, 153–72.
- ALTHAUS, C. L. (2014): “Estimating the reproduction number of Ebola virus (EBOV) during the 2014 outbreak in West Africa,” *PLoS currents*, 6.
- ARCAYA, M. C., A. L. ARCAYA, AND S. SUBRAMANIAN (2015): “Inequalities in health: definitions, concepts, and theories,” *Global health action*, 8, 27106.
- BACKUS, D. K., P. J. KEHOE, AND F. E. KYDLAND (1992): “International real business cycles,” *Journal of political Economy*, 100, 745–775.
- BAGGI, F., A. TAYBI, A. KURTH, M. VAN HERP, A. DI CARO, R. WOLFEL, S. GUNTHER, T. DECROO, H. DECLERCK, AND S. JONCKHEERE (2014): “Management of pregnant women infected with Ebola virus in a treatment centre in Guinea, June 2014,” *Eurosurveillance*.
- BECERRA, O., E. CAVALLO, AND I. NOY (2014): “Foreign aid in the aftermath of large natural disasters,” *Review of Development Economics*, 18, 445–460.
- BERTRAND, M., E. DUFLO, AND S. MULLAINATHAN (2004): “How much should we trust differences-in-differences estimates?” *The Quarterly journal of economics*, 119, 249–275.
- BHATTACHARYA, J., T. HYDE, AND P. TU (2013): *Health economics*, Macmillan International Higher Education.

- BJØRNSTAD, O. N., B. F. FINKENSTÄDT, AND B. T. GRENFELL (2002): “Dynamics of measles epidemics, estimating scaling of transmission rates using a time series SIR model,” *Ecological monographs*, 72, 169–184.
- BLANCHARD, O. J. AND D. QUAH (1988): “The dynamic effects of aggregate demand and supply disturbances,” .
- BLOOM, D. E., D. CANNING, AND G. FINK (2014): “Disease and development revisited,” *Journal of Political Economy*, 122, 1355–1366.
- BLOOM, D. E., M. KUHN, AND K. PRETTNER (2018): “Health and economic growth,” *IZA Discussion Paper*.
- BORUSYAK, K. AND X. JARAVEL (2017): “Revisiting event study designs,” *Available at SSRN 2826228*.
- CAMERON, A. C., J. B. GELBACH, AND D. L. MILLER (2008): “Bootstrap-based improvements for inference with clustered errors,” *The Review of Economics and Statistics*, 90, 414–427.
- CARTER, A. V., K. T. SCHNEPEL, AND D. G. STEIGERWALD (2017): “Asymptotic behavior of at-test robust to cluster heterogeneity,” *Review of Economics and Statistics*, 99, 698–709.
- CHAN, E. H., V. SAHAI, C. CONRAD, AND J. S. BROWNSTEIN (2011): “Using web search query data to monitor dengue epidemics: a new model for neglected tropical disease surveillance,” *PLoS neglected tropical diseases*, 5, e1206.
- CLARK, D. AND H. ROYER (2013): “The effect of education on adult mortality and health: Evidence from Britain,” *American Economic Review*, 103, 2087–2120.
- CLARK, D. V., H. KIBUUKA, M. MILLARD, S. WAKABI, L. LUKWAGO, A. TAYLOR, M. A. ELLER, L. A. ELLER, N. L. MICHAEL, A. N. HONKO, ET AL. (2015): “Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda - a retrospective cohort study,” *The Lancet Infectious Diseases*, 15, 905–912.
- COHEN, S. (2004): “Social relationships and health,” *American psychologist*, 59, 676.
- CONLEY, T. G. AND C. R. TABER (2011): “Inference with difference in differences with a small number of policy changes,” *The Review of Economics and Statistics*, 93, 113–125.
- COOK, D. A., A. J. LEVINSON, S. GARSIDE, D. M. DUPRAS, P. J. ERWIN, AND V. M. MONTORI (2008): “Internet-based learning in the health professions: a meta-analysis,” *Jama*, 300, 1181–1196.
- CUTLER, D., A. DEATON, AND A. LLERAS-MUNEY (2006): “The determinants of mortality,” *Journal of economic perspectives*, 20, 97–120.

- DJOGBENOU, A. A., J. G. MACKINNON, AND M. ORREGAARD NIELSEN (2018): “Asymptotic theory and wild bootstrap inference with clustered errors,” Tech. rep.
- DONALD, S. G. AND K. LANG (2007): “Inference with difference-in-differences and other panel data,” *The review of Economics and Statistics*, 89, 221–233.
- DÖRNEMANN, J., C. BURZIO, A. RONSSE, A. SPRECHER, H. DE CLERCK, M. VAN HERP, M.-C. KOLIÉ, V. YOSIFIVA, S. CALUWAERTS, A. K. MCELROY, ET AL. (2017): “First newborn baby to receive experimental therapies survives Ebola virus disease,” *The Journal of infectious diseases*, 215, 171–174.
- EHRHARDT, S., G. D. BURCHARD, C. MANTEL, J. P. CRAMER, S. KAISER, M. KUBO, R. N. OTCHWEMAH, U. BIENZLE, AND F. P. MOCKENHAUPT (2006): “Malaria, anemia, and malnutrition in African children defining intervention priorities,” *The Journal of infectious diseases*, 194, 108–114.
- EVANS, D. K., M. GOLDSTEIN, AND A. POPOVA (2015): *The next wave of deaths from Ebola? the impact of health care worker mortality*, The World Bank.
- FISMAN, D., E. KHOO, AND A. TUIITE (2014): “Early epidemic dynamics of the West African 2014 Ebola outbreak estimates derived with a simple two parameter model,” *PLoS currents*, 6.
- FREYALDENHOVEN, S., C. HANSEN, AND J. M. SHAPIRO (2018): “Pre event trends in the panel event study design,” Tech. rep., National Bureau of Economic Research.
- GINSBERG, J., M. H. MOHEBBI, R. S. PATEL, L. BRAMMER, M. S. SMOLINSKI, AND L. BRILLIANT (2009): “Detecting influenza epidemics using search engine query data,” *Nature*, 457, 1012.
- GONZALEZ-TORRES, A. AND E. ESPOSITO (2017): “Epidemics and Conflict-Evidence from the Ebola outbreak in Western Africa,” Tech. rep., Working Paper.
- HANSEN, C. W., P. S. JENSEN, AND P. EGEDESØ (2017): “Preventing the White Death: Tuberculosis Dispensaries,” *Available at SSRN 3036887*.
- INTERNATIONAL MONETARY FUND (2017): “Directions of Trade,” .
- JAYACHANDRAN, S. AND A. LLERAS-MUNEY (2009): “Life expectancy and human capital investments: Evidence from maternal mortality declines,” *The Quarterly Journal of Economics*, 124, 349–397.
- JORDÀ, Ò. (2005): “Estimation and inference of impulse responses by local projections,” *American economic review*, 95, 161–182.
- KERMACK, W. O. AND A. G. MCKENDRICK (1927): “A contribution to the mathematical theory of epidemics,” *Proceedings of the royal society of london*.

- Series A, Containing papers of a mathematical and physical character*, 115, 700–721.
- KIM, J. AND S. H. KIM (2003): “Spurious welfare reversals in international business cycle models,” *Journal of International Economics*, 60, 471–500.
- LEDGERWOOD, J. E., A. D. DEZURE, D. A. STANLEY, E. E. COATES, L. NOVIK, M. E. ENAMA, N. M. BERKOWITZ, Z. HU, G. JOSHI, A. PLOQUIN, ET AL. (2017): “Chimpanzee adenovirus vector Ebola vaccine,” *New England Journal of Medicine*, 376, 928–938.
- LOPEZ, A. M., R. LOOPSTRA, M. MCKEE, AND D. STUCKLER (2017): “Is trade liberalisation a vector for the spread of sugar-sweetened beverages?” *Social Science & Medicine*, 172, 21–27.
- LOZANO, R., M. NAGHAVI, K. FOREMAN, S. LIM, K. SHIBUYA, V. ABOYANS, J. ABRAHAM, T. ADAIR, R. AGGARWAL, S. Y. AHN, ET AL. (2012): “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010,” *The lancet*, 380, 2095–2128.
- MACKINNON, J. G. AND M. D. WEBB (2017): “Wild bootstrap inference for wildly different cluster sizes,” *Journal of Applied Econometrics*, 32, 233–254.
- (2018): “The wild bootstrap for few (treated) clusters,” *The Econometrics Journal*, 21, 114–135.
- MARMOT, M. (2005): “Social determinants of health inequalities,” *The lancet*, 365, 1099–1104.
- MCCLUSKEY, C. C. (2010): “Complete global stability for an SIR epidemic model with delay distributed or discrete,” *Nonlinear Analysis, Real World Applications*, 11, 55–59.
- McMICHAEL, A. J., M. MCKEE, V. SHKOLNIKOV, AND T. VALKONEN (2004): “Mortality trends and setbacks: global convergence or divergence?” *The Lancet*, 363, 1155–1159.
- MEGHIR, C., M. PALME, AND E. SIMEONOVA (2018): “Education and mortality: Evidence from a social experiment,” *American Economic Journal: Applied Economics*, 10, 234–56.
- MOULTON, B. R. ET AL. (1990): “An illustration of a pitfall in estimating the effects of aggregate variables on micro unit,” *The review of Economics and Statistics*, 72, 334–338.
- NORMAN, R. E., M. BYAMBAA, R. DE, A. BUTCHART, J. SCOTT, AND T. VOS (2012): “The long-term health consequences of child physical abuse, emotional abuse, and neglect: a systematic review and meta-analysis,” *PLoS medicine*, 9, e1001349.

- NUTT, C., V. MUSSAH, AND B. DAHN (2015): “Yes, We Were Warned About Ebola,” *The New York Times*.
- ORGANIZATION, W. H. ET AL. (2016): “Latest Ebola outbreak over in Liberia, West Africa is at zero, but new flare-ups are likely to occur,” *Retrieved January*, 14, 2016.
- PARPIA, A. S., M. L. NDEFFO-MBAH, N. S. WENZEL, AND A. P. GALVANI (2016): “Effects of response to 2014–2015 Ebola outbreak on deaths from malaria, HIV/AIDS, and tuberculosis, West Africa,” *Emerging infectious diseases*, 22, 433.
- PISCHKE, J.-S. (2005): “Empirical Methods in Applied Economics: Lecture Notes,” *Downloaded April*, 24, 2019.
- PRESTON, S. H. (1975): “The changing relation between mortality and level of economic development,” *Population studies*, 29, 231–248.
- RAVN, M. O. AND H. UHLIG (2002): “On adjusting the Hodrick-Prescott filter for the frequency of observations,” *Review of economics and statistics*, 84, 371–376.
- ROODMAN, D., M. Ø. NIELSEN, J. G. MACKINNON, AND M. D. WEBB (2019): “Fast and wild: Bootstrap inference in Stata using boottest,” *The Stata Journal*, 19, 4–60.
- ROWE, A. K., J. BERTOLLI, A. S. KHAN, R. MUKUNU, J. MUYEMBE-TAMFUM, D. BRESSLER, A. WILLIAMS, C. PETERS, L. RODRIGUEZ, H. FELDMANN, ET AL. (1999): “Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo,” *The Journal of infectious diseases*, 179, S28–S35.
- SCHMITT-GROHÉ, S. AND M. URIBE (2003): “Closing small open economy models,” *Journal of international Economics*, 61, 163–185.
- SHULGIN, B., L. STONE, AND Z. AGUR (1998): “Pulse vaccination strategy in the SIR epidemic model,” *Bulletin of mathematical biology*, 60, 1123–1148.
- SMETS, F. AND R. WOUTERS (2007): “Shocks and frictions in US business cycles: A Bayesian DSGE approach,” *American economic review*, 97, 586–606.
- SMITH, R. D., R. CHANDA, AND V. TANGCHAROENSATHIEN (2009): “Trade in health-related services,” *The Lancet*, 373, 593–601.
- SOARES, R. R. (2007): “On the determinants of mortality reductions in the developing world,” *Population and Development Review*, 33, 247–287.
- STIGLITZ, J. E. (2009): “Trade agreements and health in developing countries,” *The Lancet*, 373, 363–365.
- THE WORLD BANK (2017): “World Development Indicators,” .

- THOITS, P. A. (2010): “Stress and health: Major findings and policy implications,” *Journal of health and social behavior*, 51, S41–S53.
- WEIL, D. N. (2014): “Health and economic growth,” *Handbook of economic growth*, 2, 623–682.
- WORLD HEALTH ORGANISATION (2016): “Ebola Situation Reports: Archive,” .
- WORLD HEALTH ORGANIZATION (2018): “Global Health Workforce Statistics,” .

5 Appendix

Figure 14: Baseline Simulation Extended





Figure 15: Baseline Simulation Foreign



```

%-----
% 1. Defining variables
%-----

% 19 variables
var c1 c2 k1 k2 a1 a2 lab1 lab2 y1 y2 inv1 inv2 tb1 tb2 imp1 imp2 d1 d2 h tb1_y tb2_y;

% Declaring exogenous shock variables
varexo cp e2;

% Defining parameters
parameters gamma delta alpha beta rhoH rhoN rhoA r;

% Assigning values to parameters
% FIND SOURCES FOR VALUES
gamma=2;
delta=.05;
alpha=.32;
beta= 0.98;
rhoA= 0.42;
rhoN = 0.04;
// in-sample population autocorrelation
r = 0.04;
rhoH = 0.92;
// 0.92 as being the autocorrelation in health data for my sample

```

```

%-----
% 2.      Writing the characterizing equations
%-----

model;
// Households
exp(c2)+exp(k2)-exp(k2(-1))*(1-delta) + exp(d2) = exp(a2)*exp(lab2)^(1-alpha)*exp(k2(-1))^alpha + (1+r)* exp(d2(-1));
exp(c1)^(-gamma) = beta*exp(c1(+1))^(-gamma)*(alpha*exp(a1(+1))*exp(k1)^(alpha-1)*exp(lab1(+1))^(1-alpha) +1-delta);
exp(c2)^(-gamma) = beta*exp(c2(+1))^(-gamma)*(alpha*exp(a2(+1))*exp(k2)^(alpha-1)*exp(lab2(+1))^(1-alpha) +1-delta);
exp(c1)+exp(k1)-exp(k1(-1))*(1-delta) + exp(d1) = exp(a1)*exp(lab1)^(1-alpha)*exp(k1(-1))^alpha + (1+r)* exp(d1(-1));
exp(c1)^(-gamma) = beta * (1+r) * exp(c1(+1))^(-gamma);
exp(c2)^(-gamma) = beta * (1+r) * exp(c2(+1))^(-gamma);

// Stochastic processes
a1=rhoA*a1(-1)+h;
a2=rhoA*a2(-1)-e2;
lab1 = rhoN * lab1(-1) + h;
lab2 = rhoN * lab2(-1) - e2;

// Production
y1 = exp(a1) * exp(lab1)^(1-alpha) * exp(k1(-1))^alpha;
y2 = exp(a2) * exp(lab2)^(1-alpha) * exp(k2(-1))^alpha;

// Miscellaneous
inv1 = k1(+1) - (1-delta)*k1;
inv2 = k2(+1) - (1-delta)*k2;
tb1 = y1 - c1 - inv1;
tb2 = y2 - c2 - inv2;
imp1 = c1 + inv1;
imp2 = c2 + inv2;
h = rhoH * h(-1) - cp;
tb1_y = tb1 / y1;
tb2_y = tb2 / y2;
end;

```

```

%-----
% 3.      Initialize values (to avoid "no steady-state" solution)
%-----

initval;
k1=2.8;
k2=2.8;
c1=.8;
c2=.8;
lab1 = .3;
lab2 = .3;
inv1 = 0.6;
inv2 = 0.6;
y1 = 1;
y2 = 1;
a1=0;
a2=0;
h=1;
e2=0;
cp=0.00;
end;

%-----
% 4.      Defining the shock
%-----

shocks;
var cp;
stderr .024;
/* 0.024 is the standard deviation of the case prevalence (in percent)
in the 2014 Ebola outbreak */
end;

%-----
% 5.      Declare to solve for steady-state and simulation details
%-----

steady;
stoch_simul(dr_algo=0, order =1, hp_filter = 6.25, periods=1000, irf = 80)y1 imp1 tb1_y;
stoch_simul(dr_algo=0, order =1, hp_filter = 6.25, periods=1000, irf = 80)c1 k1 a1 lab1 inv1 d1 h;
stoch_simul(dr_algo=0, order =1, hp_filter = 6.25, periods=1000, irf = 80)k2 y2 inv2 imp2 tb2_y;

```

Table 15: Summary Statistics

| Variable | Mean | Std. Dev. | Min. | Max. | N |
|------------------------------------|---------|-----------|----------|----------|--------|
| Panel A - Health measures | | | | | |
| Adult mortality rate | 331.29 | 88.83 | 185 | 637 | 110296 |
| Adult mortality (male) | 354.65 | 87.32 | 221 | 714 | 110296 |
| Adult mortality (female) | 308.73 | 91.60 | 153 | 631 | 110296 |
| Life expectancy | 56.50 | 5.39 | 39.8 | 68.7 | 107368 |
| Life expectancy male | 55.24 | 5.18 | 38.5 | 66.7 | 107368 |
| Life expectancy female | 57.79 | 5.65 | 40.7 | 70.7 | 107368 |
| Infant mortality rate | 69.07 | 22.25 | 26.1 | 142 | 110296 |
| Neonatal mortality rate | 33.55 | 8.31 | 14.9 | 57.2 | 110296 |
| Under 5 mortality rate | 109.42 | 39.49 | 33.7 | 233.1 | 110296 |
| Crude death rate | 11.7 | 3.33 | 5.732 | 23.99 | 110296 |
| Anemia children | 67.11 | 11.16 | 36.2 | 89.90 | 110296 |
| Anemia Women | 44.18 | 10.27 | 19 | 65.3 | 110296 |
| Panel B - Output Statistics | | | | | |
| Imports (in Mil) | 40.73 | 238.02 | 0.00 | 15449.27 | 66922 |
| Exports (in Mil.) | 51.81 | 583.82 | 0 | 33710.03 | 57794 |
| Trade balance (in Mil.) | 5.87 | 446.14 | -6351.76 | 30252.98 | 79052 |
| Current account (% of GDP) | -7.34 | 10.67 | -86.09 | 21.75 | 87541 |
| Real exchange rate | 103.46 | 37.41 | 53.71 | 516.28 | 40460 |
| GDP p. c. | 925.49 | 710.13 | 193.87 | 3846.24 | 108441 |
| Panel C - Control Variables | | | | | |
| Internet access | 4.87 | 6.52 | 0.01 | 41.21 | 108999 |
| Percent migrants | 2.54 | 2.68 | 0.13 | 14.85 | 25806 |
| Population density (km^2) | 79.26 | 90.60 | 2.63 | 483.08 | 109559 |
| Living Rural (of Pop.) | 64.36 | 13.66 | 28.91 | 91.75 | 109576 |
| Living Urban (of Pop.) | 35.64 | 13.66 | 8.25 | 71.09 | 109576 |
| Health expenditure (of GDP) | 5.54 | 2.22 | 1.44 | 19.73 | 98580 |
| Net FDI (in million) | -569.45 | 1597.32 | -8235.47 | 13164.18 | 86502 |
| Price Index | 93.79 | 39.51 | 2.91 | 1592.39 | 99330 |
| Tariff rate | 13.66 | 3.78 | 0.78 | 25.17 | 80107 |
| Education expenditure | 3.86 | 1.8 | 0.83 | 13.22 | 67861 |
| Primary education | 38.70 | 21.18 | 5.17 | 88.02 | 7217 |
| Savings | 10.851 | 16.25 | -141.97 | 64.93 | 100298 |
| Fatalities | 360.62 | 1100.26 | 0 | 11546 | 109835 |
| Panel D -Other Diseases | | | | | |
| Prevalence of HIV | 51.09 | 43.92 | 1 | 145 | 118716 |
| Incidence Tuberculosis per 100,000 | 178.88 | 103.86 | 1 | 367 | 120940 |
| Incidence of malaria per 1000 | 176.39 | 100.66 | 1 | 347 | 56231 |
| Malaria cases reported | 154.13 | 85.15 | 1 | 301 | 46889 |
| CVD, cancer, diabetes or CRD | 49.63 | 26.51 | 1 | 105 | 35795 |
| Diabetes prevalence | 10.28 | 4.95 | 1 | 20 | 40 |

Table 16: Event Study Estimates

| Variables | (1) Event Study |
|-----------------|-------------------------|
| new_pre_avg_g10 | 24.38 (33.34) |
| new_pre_avg_9 | 23.10 (21.11) |
| new_pre_avg_8 | 20.78 (20.39) |
| new_pre_avg_7 | 13.33 (19.32) |
| new_pre_avg_6 | 12.37 (16.47) |
| new_pre_avg_5 | 7.617 (14.62) |
| new_pre_avg_4 | -3.642 (14.13) |
| new_pre_avg_3 | -11.57 (10.91) |
| new_pre_avg_2 | -11.54* (6.158) |
| new_avg | 178.9*** (17.81) |
| new_post_avg_1 | 57.45*** (21.00) |
| new_post_avg_2 | 41.21** (18.48) |
| time | -0.0237*** (0.00278) |
| Observations | 124,106 |
| Number of id | 7,301 |
| R^2 | 0.635 |

Clustered standard errors in parentheses

*** p<0.01, ** p<0.05, * p<0.1

The baseline year is set at $\tau - 1$, the year before the intervention.

trend represents a country-specific, linear trend.

Figure 16: Event Study Robustness




Table 17: IRF unstandardized results

| Time | (1) Case prevalence | (2) Articles | (3) Case prevalence | (4) Articles |
|--------------|------------------------|-----------------------|------------------------|-----------------------|
| τ | 0.972*** (0.317) | 0.0203*** (0.0039) | 1.15*** (0.3013) | 0.0147*** (0.0049) |
| $\tau + 1$ | -0.123* (0.0657) | 0.0056** (0.0025) | -0.7025* (0.3975) | 0.0037 (.0063) |
| $\tau + 2$ | -0.951*** (0.0401) | -0.0142*** (.0038) | -1.0209** (0.3909) | -0.0078 (.0081) |
| Control Var. | No | No | Yes | Yes |

Robust standard errors in parentheses

*** p<0.01, ** p<0.05, * p<0.1

Table 18: Balance of clusters

| Cluster Number | N | Percent |
|----------------|------|---------|
| N_1 | 5287 | 4.15 |
| N_2 | 3468 | 2.72 |
| N_3 | 3264 | 2.56 |
| N_4 | 3026 | 2.38 |
| N_5 | 3485 | 2.74 |
| N_6 | 5899 | 4.63 |
| N_7 | 3128 | 2.46 |
| N_8 | 2550 | 2 |
| N_9 | 3315 | 2.6 |
| N_10 | 3502 | 2.75 |
| N_11 | 2431 | 1.91 |
| N_12 | 2839 | 2.23 |
| N_13 | 3213 | 2.52 |
| N_14 | 3366 | 2.64 |
| N_15 | 3553 | 2.79 |
| N_16 | 3417 | 2.68 |
| N_17 | 2550 | 2 |
| N_18 | 3485 | 2.74 |
| N_19 | 2295 | 1.8 |
| N_20 | 1530 | 1.2 |
| N_21 | 3417 | 2.68 |
| N_22 | 3502 | 2.75 |
| N_23 | 3519 | 2.76 |
| N_24 | 3502 | 2.75 |
| N_25 | 3502 | 2.75 |
| N_26 | 3400 | 2.67 |
| N_27 | 3468 | 2.72 |
| N_28 | 3536 | 2.78 |
| N_29 | 3213 | 2.52 |
| N_30 | 3349 | 2.63 |
| N_31 | 2856 | 2.24 |
| N_32 | 1241 | 0.97 |
| N_34 | 3026 | 2.38 |
| N_35 | 3502 | 2.75 |
| N_36 | 3400 | 2.67 |
| N_37 | 3247 | 2.55 |
| N_38 | 3417 | 2.68 |
| N_39 | 3417 | 2.68 |

Cluster 33 has no observation
and is therefore not listed.




Figure 17: Shows the estimated confidence intervals. The results follow the baseline estimations in section ?? and include the case prevalence as the relevant measure. The upper row shows bootstrap clustering at the country level, the lower at the country-pair level. The left side follows the procedure pioneered by Cameron et al. (2008). The right column reports the additive procedure as in MacKinnon and Webb (2018).




Figure 18: Shows the estimated confidence intervals. The results follow the baseline estimations in section ?? and include the Ebola articles as the relevant measure. The upper row shows bootstrap clustering at the country level, the lower at the country-pair level. The left side follows the procedure pioneered by Cameron et al. (2008). The right column reports the additive procedure as in MacKinnon and Webb (2018).